PT Kalbe Farma Tbk 2025 AR2
The report outlines PT Kalbe Farma Tbk's performance and strategic initiatives for the fiscal year 2025. The company achieved net sales growth of 8.3% and net profit growth of 13.1%, driven by strong performance in its Prescription Pharmaceuticals and Consumer Health divisions. Key highlights include the commencement of operations at its radiopharmaceutical facility (Global Oncolab Farma) and the launch of new products like Extra Joss Ultimate. Kalbe also advanced its digital transformation through AI-driven innovations and expanded its international footprint, particularly in Southeast Asia and Africa.
Company: PT Kalbe Farma Tbk
Sector: Health Care
Country: Indonesia
Year: 2025
Type: AR2
Pages: 376
Back to company
PT Kalbe Farma Tbk
Annual Report
The report outlines PT Kalbe Farma Tbk's performance and strategic initiatives for the fiscal year 2025. The company achieved net sales growth of 8.3% and net profit growth of 13.1%, driven by strong performance in its Prescription Pharmaceuticals and Consumer Health divisions. Key highlights include the commencement of operations at its radiopharmaceutical facility (Global Oncolab Farma) and the launch of new products like Extra Joss Ultimate. Kalbe also advanced its digital transformation through AI-driven innovations and expanded its international footprint, particularly in Southeast Asia and Africa.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English, Indonesian
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees